ID: h-c2c5916913
Hypothesis
Parthenolide reduces tonic ADORA2A signaling by lowering inflammatory extracellular adenosine tone
NF-kB suppression in glia decreases ectonucleotidase and cytokine programs that sustain extracellular adenosine, indirectly reducing ADORA2A pathway output in mood circuits.
EvidencePending (0%)📖 6 cit🗣 1 debates✓ 6 support✗ 1 oppose
✓ All Quality Gates Passed
🧪 Overview
NF-kB suppression in glia decreases ectonucleotidase and cytokine programs that sustain extracellular adenosine, indirectly reducing ADORA2A pathway output in mood circuits.
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD
A["ADORA2A<br/>Hypothesis Target"]
B["Pathway Dysregulation<br/>Cited Mechanism"]
C["Cellular Response<br/>Stress or Clearance Change"]
D["Neural Circuit Effect<br/>Synapse/Glia Vulnerability"]
E["AD<br/>Disease-Relevant Outcome"]
A --> B
B --> C
C --> D
D --> E
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style B fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style E fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a⚖️ Evidence
⚖️ Evidence Matrix6 supports1 contradicts
Supports
Inflammatory adenosine tone offers a receptor-linked but indirect route to specificity.
Supports
Brain Specific RagA Overexpression Triggers Depressive-Like Behaviors in Mice via Activating ADORA2A Signaling Pathway.
Supports
Inactivation of adenosine receptor 2A suppresses endothelial-to-mesenchymal transition and inhibits subretinal fibrosis in mice.
Contradicts
Mood benefit might arise from broader anti-inflammatory effects without ADORA2A dependence.
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — ADORA2A
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for ADORA2A from GTEx v10.
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for ADORA2A.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
💰 Estimated Development
Cost
$0
Timeline
—
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▼ 0.4%
Volatility
Medium
0.0252
Events (7d)
2
Price History
▼14.1%💾 Resource Usage
LLM Tokens
1,598
$0.0048
Total Cost
$0.0048
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF parthenolide reduces extracellular adenosine tone via glial NF-κB inhibition, THEN parthenolide treatment (2 mg/kg/day, 14 days) will decrease ADORA2A-mediated cAMP accumulation in mPFC synaptoneur | At least 50% reduction in forskolin-stimulated cAMP accumulation in mPFC synaptoneurosomes from parthenolide-treated CMS mice versus vehicle-treated CMS mice, w | — no observation — | pending | 0.68 |
| IF parthenolide is administered daily at 2 mg/kg (i.p.) for 14 days to male C57BL/6J mice undergoing chronic mild stress (CMS), THEN extracellular adenosine concentrations in medial prefrontal cortex | At least 40% reduction in extracellular adenosine (μM) in mPFC of parthenolide-treated CMS mice relative to vehicle-treated CMS mice, with no significant change | — no observation — | pending | 0.72 |
🔮 Falsifiable Predictions (2)
pendingconf 72%
IF parthenolide is administered daily at 2 mg/kg (i.p.) for 14 days to male C57BL/6J mice undergoing chronic mild stress (CMS), THEN extracellular adenosine concentrations in medial prefrontal cortex (mPFC) microdialysates will decrease by at least 40% compared to vehicle-treated stressed controls,
Predicted outcome: At least 40% reduction in extracellular adenosine (μM) in mPFC of parthenolide-treated CMS mice relative to vehicle-treated CMS mice, with no signific
Falsification: Extracellular adenosine in parthenolide-treated CMS mice is NOT significantly lower than vehicle-treated CMS mice, OR adenosine levels are equally suppressed in non-stressed parthenolide-treated anima
pendingconf 68%
IF parthenolide reduces extracellular adenosine tone via glial NF-κB inhibition, THEN parthenolide treatment (2 mg/kg/day, 14 days) will decrease ADORA2A-mediated cAMP accumulation in mPFC synaptoneurosomes by ≥50% in CMS-exposed mice, while ADORA2A agonist (CGS21680)-stimulated cAMP remains intact
Predicted outcome: At least 50% reduction in forskolin-stimulated cAMP accumulation in mPFC synaptoneurosomes from parthenolide-treated CMS mice versus vehicle-treated C
Falsification: cAMP accumulation in parthenolide-treated CMS mice is NOT significantly different from vehicle controls, OR cAMP is equally reduced in non-stressed parthenolide animals, OR CGS21680 fails to stimulate
▸Metadatasource: v1_phase_c_backfill · origin_type: debate_synthesizer
| source | v1_phase_c_backfill |
| origin_type | debate_synthesizer |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.